Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
Werewolf Therapeutics (Nasdaq: HOWL), a biopharmaceutical company focused on developing conditionally activated therapeutics for cancer treatment, has announced its participation in the 7th Annual Evercore ISI HealthCONx Healthcare Conference. Daniel J. Hicklin, Ph.D., President and CEO, and Randi Isaacs, M.D., Chief Medical Officer, will engage in a fireside chat on December 5, 2024, at 12:55 pm ET in Miami, Florida. The conference runs from December 3-5, and a live webcast will be available on the company's investor website, with a replay accessible for approximately 90 days after the event.
Werewolf Therapeutics (Nasdaq: HOWL), un'azienda biofarmaceutica focalizzata nello sviluppo di terapie attivate condizionatamente per il trattamento del cancro, ha annunciato la sua partecipazione al 7° Annual Evercore ISI HealthCONx Healthcare Conference. Daniel J. Hicklin, Ph.D., Presidente e CEO, e Randi Isaacs, M.D., Chief Medical Officer, parteciperanno a una chiacchierata informale il 5 dicembre 2024, alle 12:55 ET a Miami, Florida. La conferenza si svolgerà dal 3 al 5 dicembre, e sarà disponibile una trasmissione in diretta sul sito web degli investitori dell'azienda, con una registrazione accessibile per circa 90 giorni dopo l'evento.
Werewolf Therapeutics (Nasdaq: HOWL), una empresa biofarmacéutica centrada en el desarrollo de terapias activadas condicionalmente para el tratamiento del cáncer, ha anunciado su participación en la 7ª Conferencia de Salud Evercore ISI HealthCONx. Daniel J. Hicklin, Ph.D., Presidente y CEO, y Randi Isaacs, M.D., Directora Médica, participarán en una charla informal el 5 de diciembre de 2024, a las 12:55 p. m. ET en Miami, Florida. La conferencia se llevará a cabo del 3 al 5 de diciembre, y habrá una transmisión en vivo disponible en el sitio web de inversores de la empresa, con una repetición accesible durante aproximadamente 90 días después del evento.
Werewolf Therapeutics (Nasdaq: HOWL), 암 치료를 위해 조건부 활성화 치료법 개발에 중점을 둔 생명공학 회사가 7회 연례 Evercore ISI HealthCONx 의료 회의에 참여한다고 발표했습니다. Daniel J. Hicklin, Ph.D., 사장 겸 CEO, 및 Randi Isaacs, M.D., 최고 의료 책임자가 2024년 12월 5일 오후 12:55 ET에 플로리다주 마이애미에서 진행되는 대담에 참여할 예정입니다. 회의는 12월 3일부터 5일까지 진행되며, 회사의 투자자 웹사이트에서 실시간 웹캐스트가 제공되며, 이벤트 이후 약 90일 동안 재생이 가능합니다.
Werewolf Therapeutics (Nasdaq: HOWL), une entreprise biopharmaceutique spécialisée dans le développement de thérapies activées conditionnellement pour le traitement du cancer, a annoncé sa participation à la 7e Conférence annuelle Evercore ISI HealthCONx. Daniel J. Hicklin, Ph.D., Président et CEO, et Randi Isaacs, M.D., Responsable médical, participeront à une discussion informelle le 5 décembre 2024, à 12h55 ET à Miami, Floride. La conférence se déroulera du 3 au 5 décembre, et une diffusion en direct sera disponible sur le site web des investisseurs de l'entreprise, avec une rediffusion accessible pendant environ 90 jours après l'événement.
Werewolf Therapeutics (Nasdaq: HOWL), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von bedingt aktivierten Therapeutika zur Krebsbehandlung konzentriert, hat seine Teilnahme an der 7. jährlichen Evercore ISI HealthCONx Gesundheitskonferenz angekündigt. Daniel J. Hicklin, Ph.D., Präsident und CEO, sowie Randi Isaacs, M.D., Chief Medical Officer, werden am 5. Dezember 2024 um 12:55 Uhr ET in Miami, Florida, an einem offenen Gespräch teilnehmen. Die Konferenz findet vom 3. bis 5. Dezember statt, und eine Live-Übertragung wird auf der Investoren-Website des Unternehmens verfügbar sein, mit einem Replay, das etwa 90 Tage nach der Veranstaltung zugänglich ist.
- None.
- None.
WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 12:55 pm ET on Thursday, December 5, 2024, at the 7th Annual Evercore ISI HealthCONx Healthcare Conference, taking place December 3-5 in Miami, Florida.
A live webcast link for the Evercore ISI HealthCONx Conference fireside chat will be available at https://investors.werewolftx.com/news-and-events/events. An archived replay will be available for approximately 90 days following the event.
About Werewolf Therapeutics:
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit www.werewolftx.com.
WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.
Investor Contact:
John Norton
Precision AQ
212.362.1200
john.norton@precisionaq.com
Media Contact:
Amanda Sellers
Deerfield Group
301.332.5574
amanda.sellers@deerfieldgroup.com
Company Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com
FAQ
When is Werewolf Therapeutics (HOWL) presenting at the Evercore ISI HealthCONx Conference 2024?
Where can I watch Werewolf Therapeutics (HOWL) Evercore ISI Conference presentation?
Which Werewolf Therapeutics (HOWL) executives are presenting at the 2024 Evercore Conference?
How long will the Werewolf Therapeutics (HOWL) Evercore presentation replay be available?
